Literature DB >> 34788652

Contemporary management of acute and chronic mesenteric ischemia: 10-year experience from a multihospital healthcare system.

Elizabeth A Andraska1, Lillian M Tran2, Lindsey M Haga3, Allison K Mak4, Michael C Madigan3, Michel S Makaroun3, Mohammad H Eslami3, Rabih A Chaer3.   

Abstract

OBJECTIVE: Endovascular and hybrid methods have been increasingly used to treat mesenteric ischemia. However, the long-term outcomes and risk of symptom recurrence remain unknown. The objective of the present study was to define the predictors of postoperative morbidity, mortality, and patency loss for acute mesenteric ischemia (AMI) and chronic mesenteric ischemia (CMI).
METHODS: The inpatient and follow-up records for all patients who had undergone revascularization for AMI and CMI from 2010 to 2020 at a multicenter hospital system were reviewed. Patency and mortality were evaluated with Cox regression, visualized with Kaplan-Meier curves, and compared using log-rank testing. Patency was further evaluated using Fine-Gray regression with death as a competing risk. The postoperative major adverse events (MAE) and 30-day mortality were evaluated with logistic regression.
RESULTS: A total of 407 patients were included, 148 with AMI and 259 with CMI. For the AMI group, the 30-day mortality was 31%. Open surgery was associated with lower rates of bowel resection (odds ratio [OR], 0.23; 95% confidence interval [CI], 0.13-0.61). The etiology of AMI also did not change the outcomes (OR, 1.30; 95% CI, 0.77-2.19). Adjusted analyses indicated that a history of diabetes (OR, 2.77; 95% CI, 1.37-5.61) and sepsis on presentation (OR, 2.32; 95% CI, 1.18-4.58) were independently associated with an increased risk of 30-day MAE. In the CMI group, open surgery and chronic kidney disease were associated with a higher incidence of MAE (OR, 3.03; 95% CI, 1.14-8.05; OR, 2.37; 95% CI, 1.31-4.31). In contrast, chronic kidney disease (OR, 3.02; 95% CI, 1.10-8.37) and inpatient status before revascularization (OR, 2.78; 95% CI, 1.01-7.61) were associated with increased 30-day mortality. For the CMI group, the endovascular cohort had experienced greater rates of symptom recurrence (29% vs 13%) with a faster onset (endovascular, 64 days; vs bypass, 338 days).
CONCLUSIONS: AMI remains a morbid disease despite the evolving revascularization techniques. An open approach should remain the reference standard because it reduces the likelihood of bowel resection. For CMI, endovascular interventions have improved the postoperative morbidity but have also resulted in early symptom recurrence and reintervention. An endovascular-first approach should be the standard of care for CMI with close surveillance.
Copyright © 2021 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mesenteric bypass; Mesenteric ischemia; Mesenteric stenting; Retrograde open mesenteric stenting

Mesh:

Year:  2021        PMID: 34788652      PMCID: PMC9038632          DOI: 10.1016/j.jvs.2021.11.040

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.860


  25 in total

1.  Failure to improve outcome in acute mesenteric ischaemia: seven-year review.

Authors:  N Mamode; I Pickford; P Leiberman
Journal:  Eur J Surg       Date:  1999-03

2.  The Society for Vascular Surgery clinical practice guidelines define the optimal care of patients with chronic mesenteric ischemia.

Authors:  Erica L Mitchell
Journal:  J Vasc Surg       Date:  2021-01       Impact factor: 4.268

3.  Outcomes of revascularized acute mesenteric ischemia in the American College of Surgeons National Surgical Quality Improvement Program database.

Authors:  William B Newton; Matthew J Sagransky; Jeanette S Andrews; Kimberly J Hansen; Matthew A Corriere; Philip P Goodney; Matthew S Edwards
Journal:  Am Surg       Date:  2011-07       Impact factor: 0.688

4.  Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease.

Authors:  Gustavo S Oderich; Luke S Erdoes; Christopher Lesar; Bernardo C Mendes; Peter Gloviczki; Stephen Cha; Audra A Duncan; Thomas C Bower
Journal:  J Vasc Surg       Date:  2013-07-01       Impact factor: 4.268

5.  Comparison of open and endovascular treatment of acute mesenteric ischemia.

Authors:  Robert J Beaulieu; K Dean Arnaoutakis; Christopher J Abularrage; David T Efron; Eric Schneider; James H Black
Journal:  J Vasc Surg       Date:  2013-11-05       Impact factor: 4.268

6.  Outcomes of endovascular and open treatment for chronic mesenteric ischemia.

Authors:  Jeffrey E Indes; Jeannine K Giacovelli; Bart E Muhs; Julie Ann Sosa; Alan Dardik
Journal:  J Endovasc Ther       Date:  2009-10       Impact factor: 3.487

7.  Endovascular interventions decrease length of hospitalization and are cost-effective in acute mesenteric ischemia.

Authors:  Young Erben; Clinton D Protack; Raymond A Jean; Brandon J Sumpio; Samuel M Miller; Shirley Liu; Gerardo Trejo; Bauer E Sumpio
Journal:  J Vasc Surg       Date:  2018-02-16       Impact factor: 4.268

8.  Determinants of mortality and treatment outcome following surgical interventions for acute mesenteric ischemia.

Authors:  Panagiotis Kougias; Donald Lau; Hosam F El Sayed; Wei Zhou; Tam T Huynh; Peter H Lin
Journal:  J Vasc Surg       Date:  2007-07-30       Impact factor: 4.268

9.  Retrograde open mesenteric stenting should be considered as the initial approach to acute mesenteric ischemia.

Authors:  Elizabeth Andraska; Lindsey Haga; Xiaoyi Li; Efthymios Avgerinos; Michael Singh; Rabih Chaer; Michael Madigan; Mohammad H Eslami
Journal:  J Vasc Surg       Date:  2020-04-08       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.